Olivier Rosmorduc - Researcher Profile

Publications

2 shown

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Thomas Yau , J.W. Park , Richard S. Finn +17 more

2019 Annals of Oncology 634 citations

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu , Richard S. Finn , Julien Edeline +56 more

Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in...

2018 The Lancet Oncology 2448 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 3,082
Institution: Assistance Publique – Hôpitaux de Paris

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6695-3088

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.